Recursion Begins Phase 2 Trial for AI-Developed Non-Antibiotic Treatment for Recurrent C. diff. Infection
Recursion, an AI-driven drug discovery company, has dosed the first patient in its Phase 2 ALDER trial for REC-3964, an …
News
Combatting Antibiotic Resistance: Global Superbug Map Supports Phage Therapy Development
A new global "superbug map" has been developed to track the spread of Acinetobacter baumannii, a critically antibiotic-resistant species often …
Univercells Technologies Introduces the Scale-X Nexo Bioreactor for Enhanced Cell Culture Process Development
Univercells Technologies by Donaldson has launched the scale-X nexo bioreactor, a new addition to its scale-X portfolio, designed to support …
British Patient Capital Invests £8M in Nuclera as Part of $75M Series C Funding
British Patient Capital has announced an £8 million investment in biotechnology company Nuclera, contributing to a $75 million Series C …
First Human Skin Map Could Aid in Regenerative Medicine and Scar Prevention
Researchers from the Wellcome Sanger Institute, Newcastle University, and their collaborators have created a detailed single-cell atlas of prenatal human …
clock.bio Secures $5.3M Seed Funding, Decodes Genetic Atlas of Human Rejuvenation Factors
clock.bio, a biotech company leveraging stem cell biology to extend human healthspan, has raised $5.3 million in seed funding. The …
Evaxion's AI-Immunology Platform Gains Validation in Clinical Trials
Evaxion Biotech has achieved a notable breakthrough with its AI-Immunology platform, demonstrating its capability to select effective cancer vaccine targets …
Pfizer Joins Forces with Ignition AI Accelerator to Boost AI-Driven Drug Discovery in Southeast Asia
Pfizer has entered into a partnership with the Ignition AI Accelerator to integrate artificial intelligence (AI) into its drug discovery …
XtalPi’s Ailux Biologics Enters License Agreement with Janssen Biotech to Advance AI-Powered Biologics Discovery
XtalPi Inc., an AI-driven R&D platform company, announced that its division, Ailux Biologics, has entered into a non-exclusive license agreement …
Google Research and DeepMind Unveil Tx-LLM: A New Language Model for Therapeutic Development
Google Research and DeepMind have introduced Tx-LLM, a language model designed to predict the properties of biological entities throughout the …
Recursion Pharmaceuticals Receives FDA Clearance for AI-Discovered Cancer Drug Trial
Recursion Pharmaceuticals announced that it has received FDA clearance to begin clinical trials for REC-1245, an investigational drug targeting solid …
BioPharmCatalyst Launches "Aiden," AI Chatbot for Biotech Investors
BioPharmCatalyst, a division of Scientist.com, has launched a new AI-powered chatbot named "Aiden" to deliver personalized customer service and support …